Department of Dermatology, Institut Alfred Fournier, Paris, France.
J Dermatolog Treat. 2011 Dec;22(6):359-65. doi: 10.3109/09546634.2010.499932. Epub 2010 Oct 22.
Atopic dermatitis (AD) requires permanent skin care.
A cream containing 2% SO (sunflower oleodistillate), with peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist properties, has been compared to a topical steroid (hydrocortisone butyro-propionate 1 mg/g).
An open, randomized study included two groups of 40 children (aged 3 months to 4 years). Group A applied the steroid and group B applied the 2% SO cream, twice a day. SCORAD (SCORing Atopic Dermatitis) was determined at D0, D7 and D21 and quality of life (QoL) at D0 and D21.
SCORAD was similar at D0 (37.2 versus 36.9), D7 (18.9 versus 19.2) (-49% and -48%) and D21 (11 versus 9.4) (-70% and -75%) (p < 0.01 versus D0). The Infant Dermatitis Quality of Life and Dermatitis Family Impact Questionnaire improved similarly by 65%/67% in group A and 72%/75% in group B at D21 (p < 0.01 versus D0).
A 2% SO cream has demonstrated therapeutic properties, using clinical scores and QoL, comparable to those of a topical steroid.
特应性皮炎（AD）需要持续的皮肤护理。
一种含有 2% SO（葵花油馏出物）的乳膏，具有过氧化物酶体增殖物激活受体-α（PPAR-α）激动剂特性，已与局部皮质类固醇（丁酸氢化可的松 1mg/g）进行了比较。
一项开放、随机研究纳入了两组 40 名儿童（年龄 3 个月至 4 岁）。组 A 应用皮质类固醇，组 B 应用 2% SO 乳膏，每天两次。在 D0、D7 和 D21 时评估 SCORAD（特应性皮炎评分），在 D0 和 D21 时评估生活质量（QoL）。
D0 时 SCORAD 相似（37.2 与 36.9），D7 时（18.9 与 19.2）（-49% 和 -48%），D21 时（11 与 9.4）（-70% 和 -75%）（p<0.01 与 D0 相比）。在 D21 时，组 A 和组 B 的婴儿皮炎生活质量和皮炎家庭影响问卷均改善了 65%/67%和 72%/75%（p<0.01 与 D0 相比）。
2% SO 乳膏在临床评分和 QoL 方面显示出与局部皮质类固醇相当的治疗特性。
